PDA Publishes Results of Transportation Validation Benchmarking Survey
Recommendation
22 October 2026
Good Distribution Practice of Active Substances for Human and Veterinary Medicinal Products
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In June 2025, the Parenteral Drug Association (PDA) published the results of its 2025 Transportation Validation Benchmarking Survey.
The PDA writes: "This survey aimed to gather industry benchmarking data on transportation qualification strategies within the pharmaceutical and biopharmaceutical industry. Specifically, the goal was to examine the application of simulated data to better understand how transportation conditions impact drug product quality, emphasizing the importance of ensuring product quality during transit. The survey focused on evaluating transportation through simulated environments versus real-world qualification of temperature-controlled shipping systems. [...]
To contextualize responses, the survey included general demographic questions and was structured into product-specific, supply-chain-focused, and regulatory strategy-driven categories. The manufacturers of small molecule medicines and oral dosage forms were not a target audience for this survey."
The full 40-page report (PDA Item No. 8363) is available as a PDF download on the PDA website. The price is $180 for members and $325 for nonmembers. Premium members can request a free copy until 17 July 2025.
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September